INR matters: a case on managing argatroban for bridging oral anticoagulation in a patient with heparin induced thrombocytopenia type II after mechanical heart valve replacement.
Raaz
Uwe
U
Maegdefessel
Lars
L
Buerke
Michael
M
Janusch
Matthias
M
Werdan
Karl
K
Schlitt
Axel
A
D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001021:Aortic Valve / Q000601:surgery; D001120:Arginine / Q000031:analogs & derivatives; D005260:Female; D019918:Heart Valve Prosthesis Implantation; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D019934:International Normalized Ratio; D010875:Pipecolic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D013449:Sulfonamides; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000145:classification / Q000188:drug therapy*; D016896:Treatment Outcome
D000925:Anticoagulants; D010875:Pipecolic Acids; D013449:Sulfonamides; D006493:Heparin; D001120:Arginine; C031942:argatroban